Saliva

Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”

Retrieved on: 
Wednesday, August 2, 2023
Pharmaceutical, Health, Neurology, COPD, Glaucoma, Mental toughness, Hallucination, Asthma, Psychosis, ACOR, Butyrophenone, Medicine, Education, Wheeze, Friends, Phenothiazine, Somnolence, Fever, Phenelzine, PWP Heavyweight Championship, Dopamine, Açorda, Risperidone, Fighter, Capsule, L-DOPA, Dizziness, Tranylcypromine, Patient, Gambling, Nausea, Confusion, Perspiration, Dyskinesia, Acorda Therapeutics, OFF, Metoclopramide, Upper respiratory tract infection, Therapy, Sleep, Bronchospasm, Family, Saliva, Disease, Pharmaceutical industry, Birth control, Interior design

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has launched a new INBRIJA (levodopa inhalation powder) website and brand campaign.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has launched a new INBRIJA (levodopa inhalation powder) website and brand campaign.
  • INBRIJA is not to be used by people who have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine, within the last 2 weeks.
  • I’m determined to make every day, every moment, count, and to live a full life with my family and friends.
  • The most common side effects of INBRIJA are cough, upper respiratory tract infection, nausea, and change in the color of saliva or spit.

Opteev Develops World's First Multiplex Biochip That Precisely Identifies COVID, Flu, RSV, and Respiratory Pathogens in Under 1 Minute

Retrieved on: 
Monday, July 31, 2023
Patent, Urinary tract infection, SARS-CoV-2, Patent application, Intelligence, Virology, RSV, Bacteria, Health, Virus, Saliva, Vaccine, Medical device

The groundbreaking polymer-based biochip offers the potential to test multiple pathogens responsible for respiratory infections, including SARS-CoV-2, RSV, and Influenza, and precisely identify the specific virus or bacteria in under 1 minute.

Key Points: 
  • The groundbreaking polymer-based biochip offers the potential to test multiple pathogens responsible for respiratory infections, including SARS-CoV-2, RSV, and Influenza, and precisely identify the specific virus or bacteria in under 1 minute.
  • "With the development of our multiplex biochip, we are revolutionizing point-of-care diagnostics," said Dr. Mesfin Meshesha, Vice President of Virology & Diagnostics at Opteev Technologies.
  • As Opteev Technologies continues to push the boundaries of point-of-care diagnostics, the company welcomes potential collaborations and partnerships to further develop and commercialize its multiplex biochip.
  • For more information about Opteev Technologies and its groundbreaking multiplex biochip, please visit www.opteev.com .

CE Brands Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results

Retrieved on: 
Thursday, July 27, 2023
Bankruptcy and Insolvency Act, Pressure, Uncertainty, Bankruptcy, IPhone, Interim, Partnership, Concern, Bank statement, Risk, Going concern, Conversation, Research, Biomarker, Kodak, Accounting, Forecasting, Motorola, MD, Analysis, Blood, SEDAR, Management, Ecosystem, Health, EBN, News, Saliva, Fiscal, Cryptocurrency, Mobile phone, Risk management, Marketing, Vitalism

CALGARY, Alberta, July 27, 2023 (GLOBE NEWSWIRE) -- CE Brands Inc. (TSXV: CEBI) ("CE Brands", "we", "our", or the "Company"), a data-driven consumer-electronics company, today announced its financial results for the three-month period ended March 31, 2023 ("Q4 2023") and the year ended March 31, 2023 ("Fiscal 2023").

Key Points: 
  • CALGARY, Alberta, July 27, 2023 (GLOBE NEWSWIRE) -- CE Brands Inc. (TSXV: CEBI) ("CE Brands", "we", "our", or the "Company"), a data-driven consumer-electronics company, today announced its financial results for the three-month period ended March 31, 2023 ("Q4 2023") and the year ended March 31, 2023 ("Fiscal 2023").
  • The audited consolidated financial statements for Fiscal 2023 and accompanying notes and Management's Discussion and Analysis for Fiscal 2023 ("MD&A") are available on SEDAR at www.sedar.com and on CE Brands' website at www.cebrands.ca .
  • The total revenue for Fiscal 2023 has been consistent with that of the prior year, being a decrease of 4%.
  • Net loss of approximately $28.0 million in Fiscal 2023, up by 175% compared with $10.0 million in Fiscal 2022.

Crohn's disease: bacteria in the mouth may be a cause – here's why

Retrieved on: 
Tuesday, July 25, 2023
Tissue, Human, Travel, Fatigue, Genetics, Malnutrition, Breast milk, Weight loss, Cardiovascular disease, Skin, Porphyromonas gingivalis, Research, Diarrhea, Cell, Inflammation, Fungus, Abdominal pain, Fusobacterium nucleatum, Rifaximin, Dental plaque, Mouth, Veillonella parvula, Rupture, Collection, Patient, Colorectal cancer, Immune system, Mouse, Bacteria, Ulcer, Cheek, Health, PH, Breast cancer, Smoking, Environment, Virus, Tongue, Biofilm, Meningitis, Memory, Saliva, Disease, Dietary supplement, Vaccine, Pig, Dentistry, Medical imaging, Fusobacterium

Many studies show that people with Crohn’s disease have a less diverse community of gut bacteria.

Key Points: 
  • Many studies show that people with Crohn’s disease have a less diverse community of gut bacteria.
  • But it isn’t only the gut’s bacteria that show signs of dysfunction in people with Crohn’s disease.
  • Rather unexpectedly, research also shows that the bacteria in the mouth might also be important in this inflammatory condition.

Mouth microbiome

    • As such, our mouth contains the second highest number of bacteria after the gut.
    • There are a couple of reasons why researchers think the oral microbiome might play a role in Crohn’s disease.
    • This could suggest that certain species of bacteria present in the mouth may play a role in Crohn’s disease.
    • This is perhaps unsurprising, given the entry route of bacteria into the lower gut is generally via the mouth.
    • In fact, it’s not uncommon for people with Crohn’s disease to develop ulcers in the mouth, alongside those commonly seen in the gut.

Other diseases

    • In breast cancer, the oral bacteria Fusobacterium nucleatum has been linked with accelerated tumour growth and the spread of cancer cells.
    • And although there’s plenty of data from mouse studies, more research showing this link in humans is needed.
    • Medical Research Council
      Chief Scientist Office, Scotland
      Helmsley Charitable Trust
      Jon Moulton Foundation
      Crohn's and Colitis UK
      European Research Council

RemeGen's Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren's Syndrome: Findings Published in Prestigious Rheumatology Journal

Retrieved on: 
Tuesday, July 25, 2023
Lupus, Society, RA, Peking Union Medical College Hospital, Xerostomia, Hope, Research, SLE, Rheumatoid arthritis, Patient, Oxford University Press, SS, PSS, Saliva, Immunology, EULAR, Safety, Pharmaceutical industry, Rheumatology

Rheumatology is the official journal of the British Society for Rheumatology which is published by Oxford University Press.

Key Points: 
  • Rheumatology is the official journal of the British Society for Rheumatology which is published by Oxford University Press.
  • The journal is currently included in 27 international databases and is a top journal in this field with an impact factor of 7.046 in 2021.
  • As a new drug with significant potential, telitacicept Phase II clinical study data has been published in top international journals, which is major proof of our research and development capabilities.
  • Telitacicept, a novel fully human TACI-Fc fusion protein, shows promise in inhibiting B cell maturation and reducing autoantibody production, offering significant potential disease activity control.

Essential Sprays Launches Fast-Acting and Long-Lasting Dry Mouth Spray

Retrieved on: 
Monday, July 24, 2023
Saliva, Aloe vera, Xerostomia, Coconut oil, Plaque, Tooth decay, Research, Mouth, Dentistry

ZIONSVILLE, Ind., July 24, 2023 /PRNewswire-PRWeb/ -- Today Essential Sprays announced the launch of its Dry Mouth Spray. Packaged in a 2 fl. Oz bottle that can be brought on the go, the ability to eliminate dry mouth is as fast and easy as ever.

Key Points: 
  • After seven years of research, Dr. Shane Cope created the perfect formula to eliminate dry mouth
    ZIONSVILLE, Ind., July 24, 2023 /PRNewswire-PRWeb/ -- Today Essential Sprays announced the launch of its Dry Mouth Spray .
  • Created by Dr. Shane Cope, a dentist with over 15 years of experience, Essential Sprays Dry Mouth Spray is specifically designed to rehydrate your mouth fast while protecting your teeth from cavities.
  • "After seven years of research, I finally found a fast and harmless solution to dry mouth," said Dr. Shane Cope, founder of Essential Sprays .
  • Essential Sprays Dry Mouth Spray uses powerful natural ingredients such as aloe vera and coconut oil which have been proven to effectively lubricate and rehydrate the mouth.

Prodrugs: pills your body converts into an illicit drug can evade detection, but we don't know how big the problem is

Retrieved on: 
Monday, July 24, 2023
Psychoactive drug, Cognition, Seizure, Legislation, GHB, Misuse of Drugs Act 1971, Urine, Plasma protein binding, Enzyme, Ground substance, Human, Gastric acid, Psychoactive Substances Act 2016, Emotion, LSD, COVID, Cell, Carbon, Heroin, Prodrug, GBL, Government, Stomach, Abuse, Protein, Cocaine, Metabolism, Police, Blood, Adderall, Non-Euclidean geometry, Cannabis, Ketamine, Prohibition, Death, MDMA, Saliva, Drug, Medicinal plants, Jet fuel, Medical device, Pharmaceutical industry

Prodrugs are substances that can only cause an effect after being broken down by enzymes in the digestive system or other chemical reactions in the body.

Key Points: 
  • Prodrugs are substances that can only cause an effect after being broken down by enzymes in the digestive system or other chemical reactions in the body.
  • Most illicit drugs work by interacting with specific brain cell receptors, stimulating or blocking the release of chemicals called neurotransmitters.
  • They last for a short time before being transformed into inactive or less active chemicals, which are then eliminated from the body, usually in urine.
  • For prodrugs, however, a small part of the molecule needs to be removed or substituted before it can act on those receptors.

Hard to detect

    • A major problem with prodrugs is they are difficult to detect.
    • Police forces need reference samples to compare the drug with, or advanced equipment to discover its molecular structure.
    • It also explains why many have only appeared in police reports in the past decade.
    • For biological samples (such as blood, urine or saliva), there is another difficulty.

Baylor Genetics Announces Epilepsy Panel

Retrieved on: 
Tuesday, July 11, 2023
Epilepsy, Baylor, Charcot–Marie–Tooth disease, DNA, Health care, CDKL5 deficiency disorder, Clinical trial, Rett syndrome, Angelman syndrome, DSM-IV codes, CDKL5, Genetics, Genome, Patient, Blood, Medicine, DEE, Seizure, Genetic testing, Diagnosis, Phenotype, Gene, Character, Whole genome sequencing, Skin, Sequence, Saliva, Disease, SLC6A1 epileptic encephalopathy, Pharmaceutical industry

HOUSTON, July 11, 2023 (GLOBE NEWSWIRE) -- Baylor Genetics , a clinical diagnostic laboratory at the forefront of genetic testing and precision medicine, today announced the availability of an Epilepsy Panel and a STAT Epilepsy Panel - with the latter intended for patients with new onset or change in seizure frequency or character.

Key Points: 
  • HOUSTON, July 11, 2023 (GLOBE NEWSWIRE) -- Baylor Genetics , a clinical diagnostic laboratory at the forefront of genetic testing and precision medicine, today announced the availability of an Epilepsy Panel and a STAT Epilepsy Panel - with the latter intended for patients with new onset or change in seizure frequency or character.
  • In addition to epilepsy, seen in the setting of syndromic disorders, the Baylor Genetics Epilepsy Panel offers an analysis of well-studied, actionable genes related to many non-syndromic epilepsy disorders.
  • Healthcare providers should consider ordering Baylor Genetics’ Epilepsy Panel for patients with syndromic or non-syndromic epilepsy of a suspected genetic origin.
  • Visit our convenient online ordering portal to order the new Epilepsy Panel or STAT Epilepsy Panel today.

CHA Hollywood Presbyterian to Participate in $40 Million Study of Alzheimer's Disease in Persons of Korean, Vietnamese, and Chinese Ancestry

Retrieved on: 
Tuesday, July 11, 2023
Other Consumer, Health, General Health, Seniors, Mental Health, Other Science, Research, Family, Hospitals, Consumer, Science, CHA, Perelman School of Medicine at the University of Pennsylvania, National Institute on Aging, Medical laboratory, University, Prevalence, Genetics, Cohort, Public, ACAD, NIA, SCEI, Ageing, Innovation, Multimedia, Risk, Doctor of Philosophy, Bangladesh Technical Education Board, Asian Americans, Hospital, Pathology, Blood, Multisite-specific tRNA:(cytosine-C5)-methyltransferase, University of Pennsylvania Health System, NIH, Science Publishing Group, Alzheimer's disease, Saliva, Disease, Pharmaceutical industry, Nursing

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    Alzheimer's disease poses a significant public health challenge, with increasing prevalence among aging populations worldwide.
  • However, research on this disease has limited data on its impact on people of Asian descent due to their underrepresentation.
  • ACAD is recruiting adults age 60 and older, with or without cognitive issues, from Korean, Vietnamese, and Chinese ancestry.
  • The goal of the new grant is to expand enrollment and recruit at least 5,000 participants over five years.

Multicancer Screening Global Market Report 2023: Need for Early Detection of Cancer Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, July 7, 2023
Health, Oncology, Medical Devices, CE, DNA, Prevalence, Urine, 2005 in television, Food and Drug Administration, Liquid biopsy, Cancer, RNA, Biomarker, GRAIL, Patient, Physician, Blood, LDT, Growth, Region, FDA, Food, Saliva, Illumina, Inc., Pharmaceutical industry, Medical imaging

The global multicancer screening market is projected to reach $7.78 billion by 2032 from $1.90 billion in 2022, growing at a CAGR of 15.09% during the forecast period 2023-2032.

Key Points: 
  • The global multicancer screening market is projected to reach $7.78 billion by 2032 from $1.90 billion in 2022, growing at a CAGR of 15.09% during the forecast period 2023-2032.
  • The growth in the global multicancer screening market is expected to be driven by the increased use of liquid biopsy testing and increasing prevalence of cancers.
  • Multicancer screening is a cancer screening test that has the potential to screen for more than one cancer type with a single test.
  • Some multicancer screening tests can also identify the tissue of the origin of cancer, while others need imaging tests to verify the origin.